Visit COVID-19 resources

[Skip to Content]

Eye Journal

YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome – (YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome, Published online: 2018-12-18; | doi:10.1038/s41433-018-0308-8)

Dec 18
2018

YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome, Published online: 18 December 2018; doi:10.1038/s41433-018-0308-8 YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome

  • 18 December 2018

Response to: Comment on: Eponymous women in ophthalmology: syndromes with prominent eye manifestations named after female physicians – (Response to: Comment on: Eponymous women in ophthalmology: syndromes with prominent eye manifestations named after female physicians, Published online: 2018-12-18; | doi:10.1038/s41433-018-0314-x)

Dec 18
2018

Response to: Comment on: Eponymous women in ophthalmology: syndromes with prominent eye manifestations named after female physicians Response to: Comment on: Eponymous women in ophthalmology: syndromes with prominent eye manifestations named after female physicians, Published online: 18 December 2018; doi:10.1038/s41433-018-0314-x Response to: Comment on: Eponymous women in ophthalmology: syndromes with prominent eye manifestations named after

  • 18 December 2018

Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma – (Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma, Published online: 2018-12-18; | doi:10.1038/s41433-018-0318-6)

Dec 18
2018

Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma, Published online: 18 December 2018; doi:10.1038/s41433-018-0318-6 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3

  • 18 December 2018

1-year outcomes of the Xen45 glaucoma implant – (1-year outcomes of the Xen45 glaucoma implant, Published online: 2018-12-14; | doi:10.1038/s41433-018-0310-1)

Dec 14
2018

1-year outcomes of the Xen45 glaucoma implant 1-year outcomes of the Xen45 glaucoma implant, Published online: 14 December 2018; doi:10.1038/s41433-018-0310-1 1-year outcomes of the Xen45 glaucoma implant

  • 14 December 2018

Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of Acanthamoeba keratitis – (Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of Acanthamoeba keratitis, Published online: 2018-12-14; | doi:10.1038/s41433-018-0306-x)

Dec 14
2018

Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of Acanthamoeba keratitis Torn from the headlines: role of public awareness and bench- to-bedside research in prevention and treatment of <i>Acanthamoeba</i> keratitis, Published online: 14 December 2018; doi:10.1038/s41433-018-0306-x Torn from the headlines: role of public awareness and bench- to-bedside

  • 14 December 2018